Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: A systematic review and meta-analysis
Preprint
- 28 November 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtypes classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients. Methods A systematic search was conducted in MEDLINE (PubMed), Science Direct, Scopus, and Cochrane Library databases. Studies were selected if they included Asian breast cancer patients treated with neoadjuvant chemotherapy and contained data for qualitative or quantitative analyses. The quality of the included studies was assessed using the Newcastle Ottawa Scale. Following the random effects model, pooled odds ratios or hazard ratios with 95% confidence intervals for pCR were analysed using Review Manager Software. Heterogeneity between studies was assessed using Cochran’s Q-test and I2 test statistics. Results 19,708 Asian breast cancer patients were pooled from 101 studies. In the neoadjuvant setting, taxane-anthracycline (TA) chemotherapy showed better pCR outcomes in triple negative breast cancer (TNBC) (p < 0.0001) and human epidermal growth factor receptor 2 enriched (HER2E) (p < 0.0001) than luminal breast cancer patients. Similarly, taxane-platinum (TP) chemotherapy also showed better pCR outcomes in TNBC (p < 0.0001) and HER2E (p < 0.0001). Oestrogen receptor (ER)-negative, progesterone receptor (PR)-negative, HER2-positive and high Ki-67 were significantly associated with better pCR outcomes when treated with either TA or TP. Asian breast cancer patients harbouring wildtype PIK3CA were significantly associated with better pCR outcomes when treated with TA in the neoadjuvant setting (p = 0.001). Conclusions In the neoadjuvant setting, molecular subtypes (HER2E and TNBC), biomarkers (ER, PR, HER2, HR, Ki-67, nm23-H1, CK5/6, and Tau), and gene (PIK3CA) are associated with increased pCR rates in Asian breast cancer patients. Hence, they could be further explored for their possible role in first-line treatment response, which can be utilised to treat breast cancer more efficiently in the Asian population. However, it needs to be further validated with additional powered studies. Systematic review registration: PROSPERO CRD42021246295Keywords
All Related Versions
- Version 1, 2023-11-28, Research Square
- Published version: Systematic Reviews, 13 (1), 1.
This publication has 143 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancerJournal of International Medical Research, 2013
- Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapyMedical Oncology, 2013
- Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancerJournal of Translational Medicine, 2012
- Association of HER-2 Copy Number and HER-2/CEP-17 Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast CancerThe Oncologist, 2012
- The Paradox of Triple Negative Breast Cancer: Novel Approaches to TreatmentThe Breast Journal, 2011
- Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort studyBMC Cancer, 2011
- Is Breast Cancer the Same Disease in Asian and Western Countries?World Journal of Surgery, 2010
- Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 monthsBMC Cancer, 2009
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986